Interleukin-1 beta is increased in presence of type 2 diabetes in addition to adiposity level

Paper Details

Research Paper 01/07/2012
Views (224) Download (4)
current_issue_feature_image
publication_file

Interleukin-1 beta is increased in presence of type 2 diabetes in addition to adiposity level

Ahmadi Pezhman, Torabi Mohsen, Aran Ardabili Akbar, Aghazadeh Javad
Int. J. Biosci.2( 7), 104-111, July 2012.
Certificate: IJB 2012 [Generate Certificate]

Abstract

A large body of evidence suggests an inflammatory process; characterized by adipokines production regulates islet dysfunction and insulin resistance in type 2 diabetes. The present study is an attempt to find if serum IL-lb in diabetic subjects is increased with obesity, or diabetes disorder independent of body weight and fat level affects serum levels of this cytokines. For this purpose, fasting serum IL-1b and markers indicative of type 2 diabetic such as glucose, insulin resistance and Beta-cell function were measured in middle-aged obese men with type 2 diabetic (n=16) and those without diabetic (n=16) matched for age (38 ± 5, aged) in order to compare them between two group. Anthropometrical measurements were also performed of two groups. Diabetic patients have higher fasting glucose, insulin resistance and lower beta cell function than none-diabetic subjects. Serum IL-1b in diabetic patients was also significantly higher than none-diabetic subjects. Although participants of both diabetic and non diabetic groups were classified as obese, serum IL-1b in diabetic patients was higher than another group. Based on these data, we can say the presence of diabetes affect serum IL-1b independent of body fat levels or adiposity.

VIEWS 3

Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. 2006. Inflammatory process in type 2 diabetes: The role of cytokines. Annals of the New York Academy of Sciences 1084, 89-117.

Biasucci LM, Graziani F, Rizzello V, Liuzzo G, Guidone C, De Caterina AR. 2010. Paradoxical Preservation of Vascular Function in Severe Obesity. American Journal of Medicine 123(8), 727-734.

Boni-Schnetzler MB, Thorne J, Parnaud G. 2008. Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation,” Journal of Clinical Endocrinology and Metabolism 93(10), 4065–4074.

Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S. 2003. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. American Journal of Physiological Endocrinology Metabolism 285, 527– 33.

Burns N, Finucane FM, Hatunic M, Gilman M, Murphy M, Gasparro D. 2007. Early-onset type 2 diabetes in obese white subjects is characterized by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia 50, 1500–1508.

Cris A. Charles J, Lori A, Michael T, Kim M, Joseph A. 2009. Effects of Exercise Training Intensity on Pancreatic B-Cell Function. Diabetes care 32(10), 1807-1811.

Dasu MR, Devaraj S, Jialal I. 2007. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. American Journal of Physiology – Endocrinology and Metabolism 293(1), 337-46.

Dinarello CA, Donath MY, Mandrup-Poulsen T. 2010. Role of IL-1beta in type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 17(4), 314-21.

Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N. 2009. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proceedings of the National Academy of Sciences of the United 106(33), 13998-4003.

Eizirik DL. 1988. Interleukin-1 induced impairment in pancreatic islet oxidative metabolism of glucose is potentiated by tumor necrosis factor. Acta Endocrinol (Copenh) 119, 321 -5.

Greenman Y, Golani N, Gilad S, Yaron M, Limor R, Stern N. 2004. Ghrelin secretion is modulated in a nutrient- and gender-specific manner. Clinical Endocrinology (Oxf) 60(3), 382-8.

Juge-Aubry CE, Somm E, Chicheportiche R, Burger D, Pernin A, CuenodPittet B. 2004. Regulatory effects of interleukin (IL)-1, interferon-b, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. Journal of Clinical Endocrinology & Metabolism 89, 2652– 2658.

Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulange A, Capeau J. 2006. Long-term treatment with interleukin-1b induces insulin resistance inmurine and human adipocytes.Diabetologia 49, 2162–2173.

Maedler K, Schumann DM, Sauter N. 2006. Low concentration of interleukin-1β Induces FLICE-inhibitory protein-mediated β -cell proliferation in human pancreatic islets. Diabete 55, 2713-22.

Maedler K, Dharmadhikari G, Schumann DM, Størling J. 2009. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opinion on Biological Therapy 9(9), 1177-88.

Manica-Cattani MF, Bittencourt L, Rocha MI, Algarve TD, Bodanese LC, Rech R. 2010. Association between interleukin-1 beta polymorphism (+3953) and obesity. Molecular and Cellular Endocrinology 314(1), 84-9.

Matsuki T, Horai R, Sudo K, Iwakura Y. 2003. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. Journal of Experimental Medicine 198(6), 877-88.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–9.

Moreno-Aliaga MJ, Lorente-Cebrián S, Martínez JA. 2010. Regulation of adipokine secretion by n-3 fatty acids. Proceedings of the Nutrition Society 69(3), 324-32.

Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H. 2010. Anti-inflammatory effects of excessive weight loss:potent  suppression  of  adipose  interleukin  6  and tumour necrosis factor {alpha} expression. Gut [Epub ahead of print].

Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H, Bartfai T. 2008. Treatment with and interleukin 1 beta antibody improve glycemic control in diet-induced obesity. Cytokine 44(1), 141-8.

Puglisi MJ, Fernandez ML. 2008. Modulation of C-reactive protein, tumor necrosis factor-alpha, and adiponectin by diet, exercise, and weight loss. Journal of Nutrition 138(12), 2293-6.

Pukel C, Baquerizo H, Rabinovitch A.1988. Destruction of rat islet cell monolayers by cytokines. Synergistic interactions of interferon-gamma, tumor necrosis factor ,lymphotoxin, and interleukin 1. Diabete 37, 133-6.

Ross R. 1999. Atherosclerosis: an inflammatory disease. New England Journal of Medicine 340, 115-26.

Samaras K, Botelho NK, Chisholm DJ, Lord RV. 2010. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (Silver Spring) 18(5), 884-9.

Schumann DM, Maedler K, Franklin I. 2007. The Fas pathway is involved in β -cell secretory function. Proceedings of the National Academy of Sciences of the United 104, 2861-6.

Wang C, Guan Y, Yang J. 2010. Cytokines in the Progression of Pancreatic β-Cell Dysfunction. International Journal of Endocrinology 5136.